Literature DB >> 7876619

Factors associated with early clinical recognition of children with perinatal human immunodeficiency virus infection. Northern California Pediatric HIV Consortium.

Y A Maldonado1, N E Wang, B Caldwell.   

Abstract

Surveillance of children born to women with human immunodeficiency virus (HIV) infection at five pediatric regional centers assessed times and patterns of clinical recognition in these children. Regional HIV seroprevalences among childbearing women were used to assess the proportion of identified children born to HIV-infected women. In total, 415 children with perinatal HIV exposure were identified. Early age at first HIV evaluation was significantly associated with maternal intravenous drug use (3.2 vs. 7.2 months for other or unknown maternal risk, P = .01), birth county with population > 500,000 (3.5 vs. 8.2 months for population < or = 500,000, P = .003), and hospital with routine HIV screening of pregnant women (0.1 vs. 8.8 months for no screening, P = .006). Race did not correlate with age at first evaluation. Using maternal HIV seroprevalence rates for 1988-1991, 34%-50% of the expected number of infants born to HIV-infected women were in clinical care. Perception of increased maternal risk for HIV infection was associated with early clinical recognition of infants of HIV-infected women.

Entities:  

Mesh:

Year:  1995        PMID: 7876619     DOI: 10.1093/infdis/171.3.689

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  2 in total

1.  Timing of antiretroviral therapy initiation and its impact on disease progression in perinatal human immunodeficiency virus-1 infection.

Authors:  Amy S Sturt; Meira S Halpern; Barbara Sullivan; Yvonne A Maldonado
Journal:  Pediatr Infect Dis J       Date:  2012-01       Impact factor: 2.129

2.  Temporal trends in mucocutaneous findings among human immunodeficiency virus 1-infected children in a population-based cohort.

Authors:  Amy S Sturt; Andrew Anglemyer; David R Berk; Yvonne A Maldonado
Journal:  Pediatr Dermatol       Date:  2012-11-07       Impact factor: 1.588

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.